Pradimicins: a Novel Class of Broad-spectrum Antifungal Compounds

Overview

Journal Eur J Clin Microbiol Infect Dis

Publisher Springer

Specialties Infectious Diseases
Microbiology

Date 1997 Jan 1

PMID 9063679

Citations 17

Authors

T J Walsh

N Giri

Affiliations

Soon will be listed here.

Abstract

Pradimicins are a new class of antifungal compounds currently undergoing preclinical and early phase I clinical trials. The pradimicin structure is characterized by an aglycone of dihydrobenzo (alpha) naphthacenequinone with substitutions by a D-amino acid and hexose sugar. Pradimicins possess a novel mechanism of action consisting of a specific binding recognition to terminal D-mannosides of the cell wall of Candida albicans, resulting in the formation of a ternary complex consisting of D-mannoside, pradimicin, and calcium that leads to disruption of the integrity of the fungal cell membrane. Pradimicin in the form of BMS-181184 has broad-spectrum in vitro antifungal activity against Candida spp., Cryptococcus neoformans, Aspergillus spp., dematiaceous molds, and the Zygomycetes. Fusarium spp. are comparatively resistant to high concentrations of pradimicin. Initial vivo studies indicate that pradimicins have antifungal activity against experimental murine disseminated candidiasis and disseminated aspergillosis. Early studies indicate an excellent therapeutic index with no major end-organ toxicity. Pradimicins warrant further investigation for treatment of opportunistic mycoses in immuno-compromised hosts.

Citing Articles

A Comprehensive Review on Bioactive Molecules and Advanced Microorganism Management Technologies.

Wali A, Talath S, Sridhar S, Shareef J, Goud M, Rangraze I Curr Issues Mol Biol. 2024; 46(11):13223-13251.

PMID: 39590383 PMC: 11592628. DOI: 10.3390/cimb46110789.

Exploring the frontiers of therapeutic breadth of antifungal peptides: A new avenue in antifungal drugs.

Ul Haq I, Maryam S, Shyntum D, Khan T, Li F J Ind Microbiol Biotechnol. 2024; 51.

PMID: 38710584 PMC: 11119867. DOI: 10.1093/jimb/kuae018.

Promising applications of D-amino acids in periprosthetic joint infection.

Caldwell M, Hughes M, Wei F, Ngo C, Pascua R, Pugazhendhi A Bone Res. 2023; 11(1):14.

PMID: 36894568 PMC: 9998894. DOI: 10.1038/s41413-023-00254-z.

Genetic and Biochemical Characterization of Halogenation and Drug Transportation Genes Encoded in the Albofungin Biosynthetic Gene Cluster.

Wang Z, Lo I, Lin K, Cheng A, Zadeh S, Huang Y Appl Environ Microbiol. 2022; 88(17):e0080622.

PMID: 36000868 PMC: 9469721. DOI: 10.1128/aem.00806-22.

Antimicrobial Compounds from Microorganisms.

Danquah C, Minkah P, Osei Duah Junior I, Amankwah K, Somuah S Antibiotics (Basel). 2022; 11(3).

PMID: 35326749 PMC: 8944786. DOI: 10.3390/antibiotics11030285.

References

Saitoh K, Tenmyo O, Yamamoto S, FURUMAI T, Oki T . Pradimicin S, a new pradimicin analog. I. Taxonomy, fermentation and biological activities. J Antibiot (Tokyo). 1993; 46(4):580-8. DOI: 10.7164/antibiotics.46.580. View

Aburaki S, Yamashita Y, Ohnuma T, Kamachi H, Moriyama T, Masuyoshi S . Synthesis and antifungal activity of pradimicin derivatives. Modifications of the sugar part. J Antibiot (Tokyo). 1993; 46(4):631-40. DOI: 10.7164/antibiotics.46.631. View

Walsh T, Pizzo A . Treatment of systemic fungal infections: recent progress and current problems. Eur J Clin Microbiol Infect Dis. 1988; 7(4):460-75. DOI: 10.1007/BF01962595. View

FURUMAI T, Saitoh K, Kakushima M, Yamamoto S, Suzuki K, Ikeda C . BMS-181184, a new pradimicin derivative. Screening, taxonomy, directed biosynthesis, isolation and characterization. J Antibiot (Tokyo). 1993; 46(2):265-74. DOI: 10.7164/antibiotics.46.265. View

Lyman C, Walsh T . Systemically administered antifungal agents. A review of their clinical pharmacology and therapeutic applications. Drugs. 1992; 44(1):9-35. DOI: 10.2165/00003495-199244010-00002. View

Oki T, Kakushima M, Hirano M, Takahashi A, Ohta A, Masuyoshi S . In vitro and in vivo antifungal activities of BMS-181184. J Antibiot (Tokyo). 1992; 45(9):1512-7. DOI: 10.7164/antibiotics.45.1512. View

Debono M, GORDEE R . Antibiotics that inhibit fungal cell wall development. Annu Rev Microbiol. 1994; 48:471-97. DOI: 10.1146/annurev.mi.48.100194.002351. View

Sawada Y, Hatori M, Yamamoto H, Nishio M, Miyaki T, Oki T . New antifungal antibiotics pradimicins FA-1 and FA-2: D-serine analogs of pradimicins A and C. J Antibiot (Tokyo). 1990; 43(10):1223-9. DOI: 10.7164/antibiotics.43.1223. View

Ueki T, Oka M, Fukagawa Y, Oki T . Studies on the mode of antifungal action of pradimicin antibiotics. III. Spectrophotometric sequence analysis of the ternary complex formation of BMY-28864 with D-mannopyranoside and calcium. J Antibiot (Tokyo). 1993; 46(3):465-77. DOI: 10.7164/antibiotics.46.465. View

10.

Aburaki S, Okuyama S, Hoshi H, Kamachi H, Nishio M, Hasegawa T . Synthesis and antifungal activity of pradimicin derivatives. Modifications on the aglycone part. J Antibiot (Tokyo). 1993; 46(9):1447-57. DOI: 10.7164/antibiotics.46.1447. View

11.

FURUMAI T, Kakinuma S, Yamamoto H, Komiyama N, Suzuki K, Saitoh K . Biosynthesis of the pradimicin family of antibiotics. I. Generation and selection of pradimicin-nonproducing mutants. J Antibiot (Tokyo). 1993; 46(3):412-9. DOI: 10.7164/antibiotics.46.412. View

12.

Graybill J . New antifungal agents. Eur J Clin Microbiol Infect Dis. 1989; 8(5):402-12. DOI: 10.1007/BF01964056. View

13.

Numata K, Ueki T, Naito N, Yamada N, Kamasawa N, Oki T . Morphological changes of Candida albicans induced by BMY-28864, a highly water-soluble pradimicin derivative. J Electron Microsc (Tokyo). 1993; 42(3):147-55. View

14.

Ueki T, Numata K, Sawada Y, Nishio M, Ohkuma H, Toda S . Studies on the mode of antifungal action of pradimicin antibiotics. II. D-mannopyranoside-binding site and calcium-binding site. J Antibiot (Tokyo). 1993; 46(3):455-64. DOI: 10.7164/antibiotics.46.455. View

15.

Tomita K, Nishio M, Saitoh K, Yamamoto H, Hoshino Y, Ohkuma H . Pradimicins A, B and C: new antifungal antibiotics. I. Taxonomy, production, isolation and physico-chemical properties. J Antibiot (Tokyo). 1990; 43(7):755-62. DOI: 10.7164/antibiotics.43.755. View

16.

Fung-Tomc J, Minassian B, Huczko E, Kolek B, Bonner D, Kessler R . In vitro antifungal and fungicidal spectra of a new pradimicin derivative, BMS-181184. Antimicrob Agents Chemother. 1995; 39(2):295-300. PMC: 162530. DOI: 10.1128/AAC.39.2.295. View

17.

Kamachi H, Okuyama S, Hirano M, Masuyoshi S, Konishi M, Oki T . Antifungal activities of pradimicin derivatives modified at C4'-amino group. J Antibiot (Tokyo). 1993; 46(8):1246-51. DOI: 10.7164/antibiotics.46.1246. View

18.

Sawada Y, Nishio M, Yamamoto H, Hatori M, Miyaki T, Konishi M . New antifungal antibiotics, pradimicins D and E. Glycine analogs of pradimicins A and C. J Antibiot (Tokyo). 1990; 43(7):771-7. DOI: 10.7164/antibiotics.43.771. View

19.

Saitoh K, Sawada Y, Tomita K, Tsuno T, Hatori M, Oki T . Pradimicins L and FL: new pradimicin congeners from Actinomadura verrucosospora subsp. neohibisca. J Antibiot (Tokyo). 1993; 46(3):387-97. DOI: 10.7164/antibiotics.46.387. View

20.

Oki T, Kakushima M, Nishio M, Kamei H, Hirano M, Sawada Y . Water-soluble pradimicin derivatives, synthesis and antifungal evaluation of N,N-dimethyl pradimicins. J Antibiot (Tokyo). 1990; 43(10):1230-5. DOI: 10.7164/antibiotics.43.1230. View